Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alkaloids, Hydrogenated Ergot
2. Co-dergocrine
3. Dihydroergotoxin
4. Dihydroergotoxine
5. Ergot Alkaloids, Hydrogenated
6. Circanol
7. Co Dergine Mesylate
8. Co Dergocrine Mesilate
9. Co Dergocrine Mesylate
10. Co-dergine Mesylate
11. Co-dergocrine Mesilate
12. Co-dergocrine Mesylate
13. Dihydroergotoxine Mesylate
14. Dihydroergotoxine Methanesulfonate
15. Dihydroergotoxine Monomethanesulfonate
16. Ergodesit
17. Ergoloid Mesylate
18. Ergoloid Mesylates
19. Ergotoxin, Dihydro-, Monomethasulfonate
20. Hydergine
21. Methanesulfonate, Dihydroergotoxine
22. Monomethanesulfonate, Dihydroergotoxine
23. Redergam
24. Redergin
25. Redergine
1. Ergoloid Mesilates
2. Co-dergocrine Mesylate
3. Dihydroergotoxine Mesilate
4. Dihydrogenated Ergot Alkaloids
5. Chembl2311030
6. Dihydroergotoxine Methanesulfonate
| Molecular Weight | 2715.3 g/mol |
|---|---|
| Molecular Formula | C134H184N20O32S4 |
| Hydrogen Bond Donor Count | 16 |
| Hydrogen Bond Acceptor Count | 36 |
| Rotatable Bond Count | 19 |
| Exact Mass | 2714.2301933 g/mol |
| Monoisotopic Mass | 2713.2268385 g/mol |
| Topological Polar Surface Area | 724 Ų |
| Heavy Atom Count | 190 |
| Formal Charge | 0 |
| Complexity | 4690 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 28 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 8 |
| 1 of 2 | |
|---|---|
| Drug Name | Ergoloid mesylates |
| PubMed Health | Ergoloid Mesylates (By mouth) |
| Drug Classes | Antimigraine |
| Drug Label | Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:RDihydroergocornine-CH(CH ) 32Dihydroergocristine-CH C H 265Dihydro--ergocryptine-CH CH(CH ) 232Dihydro--ergo... |
| Active Ingredient | Ergoloid mesylates |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 1mg |
| Market Status | Prescription |
| Company | Mutual Pharm |
| 2 of 2 | |
|---|---|
| Drug Name | Ergoloid mesylates |
| PubMed Health | Ergoloid Mesylates (By mouth) |
| Drug Classes | Antimigraine |
| Drug Label | Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:RDihydroergocornine-CH(CH ) 32Dihydroergocristine-CH C H 265Dihydro--ergocryptine-CH CH(CH ) 232Dihydro--ergo... |
| Active Ingredient | Ergoloid mesylates |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 1mg |
| Market Status | Prescription |
| Company | Mutual Pharm |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Co-Dergocrine Mesilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Co-Dergocrine Mesilate, including repackagers and relabelers. The FDA regulates Co-Dergocrine Mesilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Co-Dergocrine Mesilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Co-Dergocrine Mesilate supplier is an individual or a company that provides Co-Dergocrine Mesilate active pharmaceutical ingredient (API) or Co-Dergocrine Mesilate finished formulations upon request. The Co-Dergocrine Mesilate suppliers may include Co-Dergocrine Mesilate API manufacturers, exporters, distributors and traders.
click here to find a list of Co-Dergocrine Mesilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Co-Dergocrine Mesilate CEP of the European Pharmacopoeia monograph is often referred to as a Co-Dergocrine Mesilate Certificate of Suitability (COS). The purpose of a Co-Dergocrine Mesilate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Co-Dergocrine Mesilate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Co-Dergocrine Mesilate to their clients by showing that a Co-Dergocrine Mesilate CEP has been issued for it. The manufacturer submits a Co-Dergocrine Mesilate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Co-Dergocrine Mesilate CEP holder for the record. Additionally, the data presented in the Co-Dergocrine Mesilate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Co-Dergocrine Mesilate DMF.
A Co-Dergocrine Mesilate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Co-Dergocrine Mesilate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Co-Dergocrine Mesilate suppliers with CEP (COS) on PharmaCompass.
Co-Dergocrine Mesilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Co-Dergocrine Mesilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Co-Dergocrine Mesilate GMP manufacturer or Co-Dergocrine Mesilate GMP API supplier for your needs.
A Co-Dergocrine Mesilate CoA (Certificate of Analysis) is a formal document that attests to Co-Dergocrine Mesilate's compliance with Co-Dergocrine Mesilate specifications and serves as a tool for batch-level quality control.
Co-Dergocrine Mesilate CoA mostly includes findings from lab analyses of a specific batch. For each Co-Dergocrine Mesilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Co-Dergocrine Mesilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Co-Dergocrine Mesilate EP), Co-Dergocrine Mesilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Co-Dergocrine Mesilate USP).
LOOKING FOR A SUPPLIER?
